Pharmacologic manipulation of fetal hemoglobin levels in sickle cell diseases and thalassemia: promise and reality.
Pearson
H A
HA
Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut, USA.
D000755:Anemia, Sickle Cell / Q000097:blood* / Q000188:drug therapy*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000986:Antisickling Agents / Q000627:therapeutic use; D001374:Azacitidine / Q000627:therapeutic use; D004921:Erythropoietin / Q000627:therapeutic use; D005319:Fetal Hemoglobin / Q000096:biosynthesis / Q000187:drug effects*; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D010654:Phenylbutyrates / Q000627:therapeutic use; D017086:beta-Thalassemia / Q000097:blood* / Q000188:drug therapy*
D000970:Antineoplastic Agents; D000986:Antisickling Agents; D010654:Phenylbutyrates; D004921:Erythropoietin; D005319:Fetal Hemoglobin; D001374:Azacitidine; D006918:Hydroxyurea